OPKO HEALTH, INC.
No SEC Form 4 filings for $OPK in the last 30 days.
See all $OPK insider activity →OPKO Health (OPK) is positioned for growth due to RAYALDEE's performance and strategic partnerships. The company anticipates 23.3% earnings growth by 2026 and has outperformed the industry and S&P 500 year-to-date. However, risks include overdependence on RAYALDEE, clinical development risks, and macroeconomic pressures. OPK's shares have gained 17.4% YTD.
OPKO Health (OPK) trades at a discount to industry benchmarks, with improving operating trends but ongoing losses. Q2 2026 loss narrowed to $0.01 per share, and full-year loss is expected to improve. OPK has multiple clinical programs in development, with partnerships reducing funding burdens. Cash reserves stand at $314.4 million. Analysts suggest a wait-and-see approach due to mixed risk-reward profile.
OPKO Health (OPK) shares rose 12.4% in the past month due to improved operating metrics and upcoming clinical milestones. Q2 operating loss narrowed to $7M, gross profit increased to $80M, and BioReference turned profitable. Pharmaceutical revenues grew 59.8% YoY. However, OPK remains unprofitable, with risks tied to clinical execution and Medicare policy changes.
Over the past 7 days, alphai's AI scored 1 news story mentioning OPK (OPKO HEALTH, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent OPK coverage spans earnings, financial news and corporate actions.
No immediate price impact expected; the piece is largely opinion without fresh information.
Improved loss and strong cash position may support near‑term buying interest.
Improved operating metrics may sustain short‑term momentum but loss‑making status and execution risk remain.
The filing discloses a new $125M secured debt tranche tied to EirGen’s mazdutide royalty cash flows, changing near-term funding and covenant risk.
The deal provides non-dilutive funding while keeping long-term royalty participation, which can support liquidity and reduce dilution risk.
alphai scores every news story that mentions OPK with an AI model for sentiment and relevance, and aggregates insider trades from OPKO HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OPKO Health (OPK) is positioned for growth due to RAYALDEE's performance and strategic partnerships. The company anticipates 23.3% earnings growth by 2026 and has outperformed the industry and S&P 500 year-to-date. However, risks include overdependence on RAYALDEE, clinical development risks, and macroeconomic pressures. OPK's shares have gained 17.4% YTD.
3 min readOPKO Health (OPK) trades at a discount to industry benchmarks, with improving operating trends but ongoing losses. Q2 2026 loss narrowed to $0.01 per share, and full-year loss is expected to improve. OPK has multiple clinical programs in development, with partnerships reducing funding burdens. Cash reserves stand at $314.4 million. Analysts suggest a wait-and-see approach due to mixed risk-reward profile.
2 min readOPKO Health (OPK) shares rose 12.4% in the past month due to improved operating metrics and upcoming clinical milestones. Q2 operating loss narrowed to $7M, gross profit increased to $80M, and BioReference turned profitable. Pharmaceutical revenues grew 59.8% YoY. However, OPK remains unprofitable, with risks tied to clinical execution and Medicare policy changes.
2 min readOPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amen
4 min readOPKO Health said it expanded its financing with HealthCare Royalty (HCRx), a KKR business, by issuing $125 million of senior secured notes. The notes are backed by OPKO’s mazdutide royalty interests from its Eli Lilly license and mature in 2044. OPKO expects non-dilutive capital and capped total payments at 1.5x funded, while retaining long-term royalty economics. Mazdutide is commercialized in China by Innovent Biologics.
4 min readOPKO Health reported Q2 2026 revenue of $163.58M, up from $156.81M, and a reduced net loss of $8.42M versus $148.44M a year earlier, though it remained unprofitable. The company also reiterated 2026 revenue guidance of $560M to $585M, shaping expectations for cost control and progress toward break-even.
5 min readZacks upgraded OPKO Health (OPK) to a Zacks Rank #2 (Buy), citing rising earnings estimates. The Zacks Consensus Estimate increased 11.6% over the past three months. For FY ending Dec 2026, OPK is expected to earn -$0.26 EPS, unchanged year over year, according to Zacks.
5 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readOpko Health shares rose about 33% Tuesday after the company reported Q2 results. Revenue increased 4% to $163.5M and the net loss narrowed to $8.4M, or $0.01 per share. Opko also raised 2026 revenue guidance to $560M-$585M, above prior guidance and analyst estimates.
4 min readSimply Wall St reports OPKO Health (OPK) shares rose about 33% to around $1.65 after Q2 2026 results showed net loss narrowing to $8.4 million from $148.4 million on revenue of $163.6 million. Operating loss fell to about $7.0 million. The article cites diagnostics profit and ModeX pipeline enrollment progress, with cash above $300 million.
4 min read
